191 related articles for article (PubMed ID: 23091827)
21. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Edwards DB; Silverberg J
Ann Intern Med; 2011 Apr; 154(8):570; author reply 570-1. PubMed ID: 21502658
[No Abstract] [Full Text] [Related]
22. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.
Nagarakanti R; Ezekowitz MD; Oldgren J; Yang S; Chernick M; Aikens TH; Flaker G; Brugada J; Kamensky G; Parekh A; Reilly PA; Yusuf S; Connolly SJ
Circulation; 2011 Jan; 123(2):131-6. PubMed ID: 21200007
[TBL] [Abstract][Full Text] [Related]
23. Massive left atrial thrombus in a patient with rheumatic mitral stenosis and atrial fibrillation while anticoagulated with dabigatran.
Luis SA; Poon K; Luis C; Shukla A; Bett N; Hamilton-Craig C
Circ Cardiovasc Imaging; 2013 May; 6(3):491-2. PubMed ID: 23696587
[No Abstract] [Full Text] [Related]
24. Place of dabigatran in contemporary pharmacotherapy.
Gums JG
Pharmacotherapy; 2011 Apr; 31(4):335-7. PubMed ID: 21449622
[No Abstract] [Full Text] [Related]
25. Update on dabigatran for stroke prevention in atrial fibrillation.
Henry DM
Conn Med; 2011 Sep; 75(8):479-83. PubMed ID: 21980679
[No Abstract] [Full Text] [Related]
26. Dabigatran-related intracerebral hemorrhage resulting in hematoma expansion.
Simonsen CZ; Steiner T; Tietze A; Damgaard D
J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):e133-4. PubMed ID: 24103671
[TBL] [Abstract][Full Text] [Related]
27. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Chan KE; Edelman ER; Wenger JB; Thadhani RI; Maddux FW
Circulation; 2015 Mar; 131(11):972-9. PubMed ID: 25595139
[TBL] [Abstract][Full Text] [Related]
28. Avoiding adverse events with dabigatran by careful selection of eligible patients.
Baker RI; Harper P; McLintock C
Med J Aust; 2012 Apr; 196(7):431-2. PubMed ID: 22509863
[No Abstract] [Full Text] [Related]
29. Risk of major bleeding and the standard doses of dabigatran.
Antoniazzi S; Berdaï D; Conti V; Clementi E; Salvo F
Eur J Intern Med; 2014 Jul; 25(6):e73-5. PubMed ID: 24629895
[No Abstract] [Full Text] [Related]
30. [Fewer strokes, lower mortality. Large general practice studies confirm good safety profile of dabigatran].
Einecke D
MMW Fortschr Med; 2014 Dec; 156(21-22):28, 30. PubMed ID: 25608388
[No Abstract] [Full Text] [Related]
31. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY
Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
[TBL] [Abstract][Full Text] [Related]
32. Stroke prevention in nonvalvular atrial fibrillation.
Ganjehei L; Massumi A; Razavi M; Rasekh A
Tex Heart Inst J; 2011; 38(4):350-2. PubMed ID: 21841857
[No Abstract] [Full Text] [Related]
33. Namibia becomes first country in Africa to launch dabigatran etexilate for atrial fibrillation.
Wagenaar P
Cardiovasc J Afr; 2011; 22(5):283. PubMed ID: 21983957
[No Abstract] [Full Text] [Related]
34. [Anticoagulant therapy in stroke patients].
Kraglund KL; Husted SE; Modrau B; Grove EL
Ugeskr Laeger; 2013 Jan; 175(5):265-8. PubMed ID: 23369327
[TBL] [Abstract][Full Text] [Related]
35. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
Pengo V; Crippa L; Falanga A; Finazzi G; Marongiu F; Palareti G; Poli D; Testa S; Tiraferri E; Tosetto A; Tripodi A; Manotti C;
Thromb Haemost; 2011 Nov; 106(5):868-76. PubMed ID: 21946939
[TBL] [Abstract][Full Text] [Related]
36. Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Lane DA; Wood K
Circulation; 2015 Apr; 131(16):e412-5. PubMed ID: 25901074
[No Abstract] [Full Text] [Related]
37. An anticoagulation option for nonvalvular atrial fibrillation.
Shaheen MH; Das P; Koshy SK; Jha SK; Kabra R
J Fam Pract; 2012 Jun; 61(6):E1-6. PubMed ID: 22670241
[No Abstract] [Full Text] [Related]
38. Use of dabigatran to prevent stroke in patients with atrial fibrillation.
Mooney T
Nurs Stand; 2013 Mar 6-12; 27(27):35-41. PubMed ID: 23556305
[TBL] [Abstract][Full Text] [Related]
39. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.
Cove CL; Hylek EM
J Am Heart Assoc; 2013 Oct; 2(5):e000136. PubMed ID: 24152980
[No Abstract] [Full Text] [Related]
40. Benefits of dabigatran maintained for more than two years.
Aalbers J
Cardiovasc J Afr; 2012 Nov; 23(10):576. PubMed ID: 23192264
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
